AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25681139
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment with thiazides, alpha-methyldopa, and propranolol; n = 406
Trial: 18446389
Drug: Scaling, root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling, root planning, and chlorhexidine rinses for 3 months with systemic administration of doxycycline (100 mg once a day for 15 days)
Trial: 18446389
Drug: Scaling, root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling, root planning, and chlorhexidine rinses for 3 months without systemic administration of doxycycline
Trial: 16531178
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by vaginal misoprostol 800 mcg after 6-8 hours
Trial: 16531178
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by vaginal misoprostol 800 mcg after 24 hours
Trial: 21881569
Drug: Spironolactone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (400 mg)
Trial: 23303058
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 mg at 2300 hours)
Trial: 21112791
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MGSS and clinical palpation
Trial: 6138060
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg midazolam
Trial: 6138063
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg midazolam
Trial: 6138063
Drug: Midazolam (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (10, 20, 30 mg)
Trial: 3718586
Drug: Brotizolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam (0.25 mg)
Trial: 21463150
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus CABG
Trial: 21463153
Drug: Treatment assignment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assignment
Trial: 9190629
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy (low dose)
Trial: 2936564
Drug: Nafarelin acetate
RxNorm normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate 125 micrograms daily
Trial: 2936564
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of nafarelin acetate
Trial: 17135988
Drug: Clinical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical management with pill placebo
Trial: 14514569
Drug: Pravastatin therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin therapy, 40 mg/day over 6.0 years
Trial: 9285143
Drug: Urinary IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary IgG excretion
Trial: 9285143
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum albumin and transferrin, high urinary transferrin, beta-microglobulin, and IgG excretion
Trial: 8360131
Drug: Amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin 15 mg/kg/day given as a single dose (once-daily)
Trial: 8360131
Drug: Amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin 15 mg/kg/day given in two divided doses at 12 h intervals (twice-daily)
Trial: 3526986
Drug: one inhalation
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one inhalation isoetharine mesylate (IM)
Trial: 3526986
Drug: one inhalation
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one inhalation placebo (P)
Trial: 26837471
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell‐based inactivated EV71 vaccine
Trial: 17313873
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 0.5 mg daily for at least 52 weeks
Trial: 17313873
Drug: Lamivudine (LVD)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (LVD) 100 mg daily for at least 52 weeks
Trial: 12505243
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group
Trial: 8590144
Drug: H. pylori-positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori-positive after treatment
Trial: 2665761
Drug: Selective digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective digestive decolonization (SDD) with non-resorbable antibiotics: 4 x 100 mg of polymyxin B, 4 x 500 mg of amphotericin B, and 4 x 80 mg of tobramycin via gastric tube.
Trial: 2665761
Drug: Selective digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective digestive decolonization (SDD) with non-resorbable antibiotics.
Trial: 2665761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SDD treatment).
Trial: 21886949
Drug: Upper Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper Body Resistance Training (UBRT) for 4 weeks, 3 times weekly
Trial: 14750577
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg/day for 16 weeks)
Trial: 26741286
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) administration (40 IU)
Trial: 25421781
Drug: Telephone-delivered physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered physical activity intervention (pedometers and eight weekly phone calls)
Trial: 18823000
Drug: Web-based, self-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based, self-guided alcohol treatment program
Trial: 10418756
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (STD)
Trial: 27136447
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and acupuncture combined therapy
Trial: 25174484
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mannitol
Trial: 19952822
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg x kg(−1) caffeine
Trial: 19952822
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg x kg(−1) caffeine
Trial: 9920950
Drug: Twice-daily thoracic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily thoracic radiotherapy (45 Gy over three weeks)
Trial: 9920950
Drug: Once-daily thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily thoracic radiotherapy (45 Gy over five weeks)
Trial: 9920950
Drug: Twice-daily thoracic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily thoracic radiotherapy
Trial: 9920950
Drug: Once-daily thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily thoracic radiotherapy
Trial: 7731455
Drug: Intraportal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraportal infusion of 5-fluorouracil (500mg per day) for 14 days from 21 postoperative days and lipiodol-aclarubicin (40mg) at 35 POD
Trial: 7731455
Drug: Intraportal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraportal infusion of 5-fluorouracil and lipiodol-aclarubicin
Trial: 1665176
Drug: Lisinopril-Hydrochlorothiazide 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril-Hydrochlorothiazide 20 mg/12.5 mg
Trial: 1665176
Drug: Lisinopril-Hydrochlorothiazide 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril-Hydrochlorothiazide 20 mg/25 mg
Trial: 7789045
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg
Trial: 7927956
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg
Trial: 7378250
Drug: Isoprenaline infusion
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline infusion intravenously at different rates
Trial: 24768290
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (30 mg)
Trial: 26193882
Drug: Individualised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised physical activity on prescription (PAP) for 6 months
Trial: 20212249
Drug: DD (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DD (both doses)
Trial: 18035198
Drug: Fluvastatin (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20, 40, and 80 mg daily)
Trial: 15727648
Drug: Altoderm lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altoderm lotion
Trial: 9840118
Drug: Tauroursodeoxycholic acid
RxNorm normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tauroursodeoxycholic acid (500 mg or 750 mg daily for 6 months)
Trial: 8302553
Drug: Fluorescein solution
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescein solution (5 microliters) administered under the upper lid
Trial: 8302553
Drug: Fluorescein solution
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescein solution (5 microliters) administered under the lower lid
Trial: 9554429
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/d)
Trial: 29189044
Drug: Desvenlafaxine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (25-50 mg/d)
Trial: 24761877
Drug: Glycididazole sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycididazole sodium (CMNa) 800 mg/m2 before radiotherapy, administered by intravenous drip, three times a week
Trial: 8752611
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive therapy (30 micrograms ethinyl E2 plus 150 micrograms desogestrel)
Trial: 8752611
Drug: Cyclic oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic oral contraceptive therapy
Trial: 8752611
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a, leuprolide acetate depot 3.75 mg)
Trial: 8752611
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive therapy
Trial: 1790313
Drug: Capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation administered with water or milk
Trial: 29560937
Drug: Submaximal doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submaximal doses of mexidol (750 mg infusion in 250 ml of 0.9% NaCl solution for 6 days)
Trial: 27129606
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam
Trial: 11576093
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg x kg(‐1)
Trial: 7711149
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition guideline involving a commercialized enteral diet administered in 6 sessions at three-hour intervals, starting with 100 cc per session up to a total of 400 cc (2400 kcal/day) with 100 cc of water added.
Trial: 2523656
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 to 20 mg twice daily
Trial: 2894890
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 to 100 mg once daily
Trial: 826948
Drug: Nootropyl (Piracetam)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nootropyl (Piracetam) 400 mg per day for 14 days
Trial: 26975498
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula oxygen therapy
Trial: 20632888
Drug: 5-microg whole-virion
RxNorm normalized name: Acetosella acetosella whole
DrugBank: Rumex acetosella whole (DB14166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-microg whole-virion aluminum formulation
Trial: 20632888
Drug: 30-microg split-virion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-microg split-virion nonaluminum formulation
Trial: 20632888
Drug: 15-microg split-virion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-microg split-virion formulation
Trial: 27801706
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT)
Trial: 14687955
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous depot injection of 58 mg buprenorphine
Trial: 15197803
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan (HDM)
Trial: 31703653
Drug: High birth
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High birth weight (BW ≥ 3500 g)
Trial: 25961283
Drug: Ad35-GRIN followed
RxNorm normalized name: GRINDELIA CILIATA POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35-GRIN followed by two doses of F4/AS01B
Trial: 25961283
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of an adjuvanted protein and an adenovirus vector
Trial: 16420273
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (pseudo-application)
Trial: 9394367
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (general)
Trial: 20107214
Drug: Pooled vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled vaccine group (two or three doses of vaccine)
Trial: 20107214
Drug: Pooled vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled vaccine group
Trial: 22677305
Drug: Diclofenac-K 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac-K 12.5 mg tablets
Trial: 20541301
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,200 mg orally, 4 doses at 12-hour intervals
Trial: 15565899
Drug: Topical mupirocin
RxNorm normalized name: mupirocin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mupirocin treatment
Trial: 30591656
Drug: Preventive Zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive Zinc (PZ) tablets (7 mg/day)
Trial: 30591656
Drug: Therapeutic Zinc
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Zinc (TZ) supplements for diarrhea treatment (20 mg/day for 10 days)
Trial: 30591656
Drug: Multiple Micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Micronutrient Powder (MNP) sachets (10 mg zinc and 14 other micronutrients)
Trial: 27574788
Drug: AZD5069 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5069 5 mg
Trial: 27574788
Drug: AZD5069 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5069 15 mg
Trial: 25201763
Drug: Frequent skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent skin care (oil bath (0.5 dl) and facial fat cream)
Trial: 25471197
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg caffeine
Trial: 19200991
Drug: 75 IU
RxNorm normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 IU of rLH daily for 4 days
Trial: 10390007
Drug: ECF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECF regimen (epirubicin, cisplatin, and protracted venous infusion fluorouracil)
Trial: 8430924
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 300 micrograms daily
Trial: 29763659
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI 160/14.4/10 μg
Trial: 9359442
Drug: Anti-inflammatory therapy
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory therapy
Trial: 8942455
Drug: Supportive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive group therapy
Trial: 17295570
Drug: Interpretive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpretive group therapy
Trial: 25736422
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy
Trial: 8877209
Drug: Adenoidectomy (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoidectomy (in combination with other minor procedures)
Trial: 27227692
Drug: Pain Coping
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Coping Skills Training (cognitive behavioral therapy)
Trial: 24497963
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/d added to interferon beta-1b (IFNB-1b)
Trial: 24497963
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (IFNB-1b) monotherapy
Trial: 1781761
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate cream 0.1% applied once daily
Trial: 10489492
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate cream 0.05% applied twice daily
Trial: 1874210
Drug: Etomidate 1
RxNorm normalized name: metomidate 1000 mg in 1 g TOPICAL POWDER [Aquacalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 1 mg kg‐1 followed by 1 mg kg‐1 h‐1
Trial: 1874210
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg kg‐1 followed by 9 mg kg‐1 h‐1
Trial: 23241930
Drug: Meriva® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meriva® (2 tablets/day, each containing 500 mg Meriva® corresponding to 100 mg curcumin) for at least 4 weeks
Trial: 10437219
Drug: Propafenone (Western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (Western drug)
Trial: 7850847
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine (CHX) gel for 5 min/day for 9 days followed by 0.4% stannous fluoride (SnF2) gel for 14 days
Trial: 30312595
Drug: Patient-centered graded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered graded exposure intervention added to manual therapy
Trial: 28383927
Drug: Daily activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activities writing (writing objectively about daily activities)
Trial: 21190917
Drug: Test Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test Clarithromycin tablets 500 mg
Trial: 21190917
Drug: Reference Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference Clarithromycin tablets 500 mg
Trial: 18501094
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies (e.g., cetuximab, bevacizumab)
Trial: 8848912
Drug: Doxapram 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram 0.5 mg.kg-1
Trial: 8848912
Drug: Doxapram 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram 0.5 mg.kg-1 with alfentanil pre-treatment
Trial: 28953856
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (0, 1, or 2 mg/kg/day) from 6 weeks to 6 months of age
Trial: 28953856
Drug: Combined supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplemented groups (1 or 2 mg/kg/day)